Avadel Pharmaceuticals Plc's (NASDAQ:AVDL) Path To Profitability
Oppenheimer's Top SMID Ideas Within High-growth Themes
Avadel Pharmaceuticals to Join Russell 3000 Index
Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $29
Rodman & Renshaw Initiates Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Announces Target Price $27
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
Avadel Pharmaceuticals: Appointment Effective May 17, 2024 >AVDL
Express News | Avadel Pharmaceuticals Appoints Naseem Amin, M.d. to Its Board of Directors
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
Avadel Gains for a Second Day as Analysts See It Prevailing in Case Vs Jazz/FDA
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
Avadel Pharma Gains During Hearing Over Dispute on FDA Approval of a Sleep Disorder Drug
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%
Buy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market Expansion
Avadel Pharmaceuticals Plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $27
Avadel Pharmaceuticals Is Maintained at Buy by Craig-Hallum